Published Work
Published Work
Publications & Selected Abstracts
Explore published research from Tisch MSRCNY
Stem cell therapy in multiple sclerosis: a future perspective
Neurodegenerative Disease Management, 5(3), 167–170. Harris, V. K., & Sadiq, S. A.
Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis
Cytotherapy. 2016 Dec;18(12):1476-1482. Harris VK, Vyshkina T, Sadiq SA.
Biomarkers of multiple sclerosis: Current Findings
Degener Neurol Neuromuscul Dis. 2017 Jan 12;7:19-29. Harris VK, Tuddenham JF, Sadiq SA.
Fetuin-A deficiency protects mice from Experimental Autoimmune Encephalomyelitis (EAE) and correlates with altered innate immune response
PLoS One. 2017 Apr 7;12(4):e0175575. Harris VK, Bell L, Langan RA, Tuddenham J, Landy M, Sadiq SA.
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis
EBioMedicine. 2018 Mar;29:23-30. Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA.
Mesenchymal stem cell-derived neural progenitors attenuate proinflammatory microglial activation via paracrine mechanisms
Regenerative Medicine, 18(3), 259–273. Harris, V. K., Bishop, D., Wollowitz, J., Carling, G., Carlson, A. L., Daviaud, N., & Sadiq, S. A.
Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial
Stem Cell Res Ther 15, 151 (2024). Harris, V.K., Stark, J., Williams, A. et al.
